Plus   Neg

Illumina Tanks 13% As Q2 Results Miss Estimates

Shares of Illumina Inc. (ILMN) slipped more than 13% in after-hours trading after the biotech company reported a second-quarter results that fell short of Wall Street expectations, hurt largely pandemic-related disruptions.

Second-quarter net income was $47 million or $0.32 per share, compared to $296 million or $1.99 per share last year.

Adjusted income for the quarter was $92 million or $0.62 per share, compared to $200 million or $1.35 per share last year.

Revenues for the quarter dropped 25% to $633 million from $838 million last year.

Analysts polled by Thomson Reuters expected earnings of $0.67 per share on revenues of $679.56 million for the quarter.

"As expected, the second quarter was significantly impacted by pandemic-related disruption in our customers' operations and was particularly challenging for many of our research customers who remain closed or operating at limited scale," said Francis deSouza, President and CEO. "It is clear that the role of genomics in infectious disease will continue to grow through and beyond this pandemic."

ILMN closed Thursday's trading at $399.33, down $1.41 or 0.35%, on the Nasdaq. The stock further dropped $52.45 or 13.13% in the after-hour trading.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform U.S. airline Delta Air Lines, Inc. and its Italian codeshare partner Alitalia are planning to launch quarantine-free, COVID-free flights between U.S. and Europe through new testing protocols, starting in December. In a statement, Delta said it has signed deals with airports and governments eliminating quarantine requirements on COVID-tested flights connecting Atlanta and Rome.
Follow RTT